Sim John J, Chen Qiaoling, Cannizzaro Nancy, Bhandari Simran K, Fernandes Ancilla W, Chang John, Pinto Cibele, Schachter Asher D, Mathur Mohit
Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, USA.
Department of Research and Evaluation, Pasadena, California, USA.
Am J Nephrol. 2025;56(2):172-177. doi: 10.1159/000541869. Epub 2024 Nov 4.
IgA nephropathy (IgAN), a leading cause of kidney failure worldwide, is one of the most common forms of primary glomerulonephropathy with variability by race and ethnicity. Using a diverse cohort within a large integrated health system in the United States (US), we identified and characterized patients with biopsy-proven IgAN and report annual incidence rates across racial/ethnic groups and standardized to the US nationally.
A cross-sectional study between January 1, 2010, and December 31, 2021 within Kaiser Permanente Southern California was performed. Patients (age >/=18 years) who underwent a native kidney biopsy and identified as having primary IgAN comprised the study population. Laboratory, demographic, and comorbidity information were obtained from the electronic health records. Annual incidence rates were calculated for biopsy-proven IgAN (per 100,000 person-years) and standardized to 2020 US Census.
Of 9,392 individuals who underwent kidney biopsy, 606 adult patients were identified with primary IgAN. Crude annual IgAN incidence rates ranged from 1.3 to 2.2 (per 100,000 person-years). US census standardized incidence rate (CI) of IgAN was 1.4 (0.8, 2.0) per 100,000 person-years in the 12-year period. Incidence rate (per 100,000 person-years) was highest among Asian/Pacific Islander (4.5) and Hispanic (1.7) patients and lowest among White (1.2) and Black (0.6) patients. Median estimated glomerular filtration rate (eGFR) was 51 mL/min with median urine protein creatinine ratio (uPCR) 1.8 g/g.
Among a large diverse US population within Southern California, we observed an IgAN incidence rate of 1.7 which estimated to a standardized US incidence of 1.4 (per 100,000 person-years) within a 12-year period. Patients appear to be diagnosed at more advanced disease given kidney function and proteinuria at biopsy.
IgA肾病（IgAN）是全球肾衰竭的主要原因之一，是原发性肾小球肾病最常见的形式之一，在不同种族和民族中存在差异。我们在美国一个大型综合医疗系统中使用了一个多样化的队列，识别并描述了经活检证实为IgA肾病的患者，并报告了各种族/民族群体的年发病率，并根据美国全国标准进行了标准化。
在2010年1月1日至2021年12月31日期间，在南加州凯撒医疗集团进行了一项横断面研究。接受过肾活检并被确定为患有原发性IgA肾病的患者（年龄≥18岁）构成了研究人群。实验室、人口统计学和合并症信息从电子健康记录中获取。计算经活检证实的IgA肾病的年发病率（每10万人年），并根据2020年美国人口普查进行标准化。
在9392名接受肾活检的个体中，606名成年患者被确定患有原发性IgA肾病。IgA肾病的粗年发病率在1.3至2.2（每10万人年）之间。在这12年期间，IgA肾病的美国人口普查标准化发病率（CI）为每10万人年1.4（0.8，2.0）。发病率（每10万人年）在亚洲/太平洋岛民（4.5）和西班牙裔（1.7）患者中最高，在白人（1.2）和黑人（0.6）患者中最低。估计肾小球滤过率（eGFR）中位数为51 mL/分钟，尿蛋白肌酐比值（uPCR）中位数为1.8 g/g。
在南加州一个多样化的美国人群中，我们观察到IgA肾病的发病率为1.7，估计在12年期间标准化的美国发病率为1.4（每10万人年）。鉴于活检时的肾功能和蛋白尿情况，患者似乎在疾病更晚期才被诊断出来。
